Economic evaluation of gene-replacement therapies: abstract highlights from day 2 of ISPOR Europe 2019

As part of our continuous coverage of the ISPOR Europe 2019 (2–6 November; Copenhagen, Denmark) meeting, we bring you our abstract highlights from the second day of the conference: gene therapies, acute coronary syndrome and more!

Go to the profile of The Evidence Base
Nov 05, 2019
0
0

Abstract highlights:

Economic evaluation of gene-replacement therapies: challenges and potential methodological solutions
Acute coronary syndrome; resource use and costs
A budget-impact analysis of somatostatin analogues for the treatment of gastroenteropancreatic cancer and acromegaly


Economic evaluation of gene-replacement therapies: challenges and potential methodological solutions

Researchers from Creativ-Ceutical (Luxembourg) and Aix-Marseille University (Marseille, France) have conducted a literature review, alongside interviews with eight, leading health economists, to determine potential solutions to methodological issues associated with the economic evaluation of gene-replacement therapies. Current challenges to this include the accurate assessment of gene-replacement therapies’ clinical effectiveness and safety, and the determination of health outcomes values.

Whilst the researchers concluded that certain limitations associated with economically evaluating gene-replacement therapies are inherent to the limited availability of clinical data, by generating methodological research from health economists, some limitations may be able to be mitigated. Key proposal for improving the process of economic evaluation of gene replacement therapies include employing a social perspective to elicit health state utilities, paying consideration to elements of value that are often ignored – such as the value of hope and value of cure – and weighting quality-adjusted life year calculation differently according to individuals’ age groups.

Read more

Back to top of page


Acute coronary syndrome; resource use and costs

Real Life Data SLU and Hospital Universitari Germans Trias i Pujol (both Barcelona, Spain) researchers have conducted a literature review of clinical trials and observational studies to determine the key healthcare costs associated with acute coronary syndrome (ACS). A total of 38 articles were reviewed; data on ACS patients’ clinical management was collected and categorized according to 1) patients’ initial evaluation, 2) the confirmation acute coronary syndrome diagnosis, 3) patients’ risk assessment, 4) the selection of the type of revascularization treatment and 5) individuals’ hospital discharge and the follow-up.

The study revealed that significant heterogeneity exists in adherence to clinical practice guideline recommendations for ACS patients. The highest healthcare costs associated with ACS stem from hospital admissions and re-admissions; this highlights the importance of primary prevention strategies and more aggressive secondary strategies for ACS to reduce the high associated healthcare costs.

Read more

Back to top of page


A budget-impact analysis of somatostatin analogues for the treatment of gastroenteropancreatic cancer and acromegaly

Both lanreotide autogel and octreotide LAR are long-acting analogues of somatostatin, approved in the UK, for the treatment of gastroenteropancreatic neuroendocrine tumors and acromegaly. The administration routes of these treatments differ with regards to their need for injection by a health care professional and dosing interval. In this study, researchers from the UK and France have conducted a budget-impact analysis of lanreotide autogel and octreotide LAR, accounting for differences in drug delivery between these long-acting somatostatin analogues.

The results of the study demonstrate that increasing the prescription of lanreotide autogel to gastroenteropancreatic cancer and acromegaly patients to 80% – from the current 56.3% – would reduce total long-acting somatostatin analogue treatment costs by £2.9 million annually. This could significantly improve the overall efficiency of the UK healthcare system.

Read more

Back to top of page


Stop by booth #C2-026 to meet The Evidence Base® and Journal of Comparative Effectiveness Research teams, and receive a free gift!




Go to the profile of The Evidence Base

The Evidence Base

Community, Future Medicine

The Evidence Base is a community site covering the latest news, opinion and insight into the collection and application of real-world data to real-world problems.
55 Contributions
4 Followers
0 Following

No comments yet.